Back to top
more

National Vision Holdings, Inc. (EYE)

(Delayed Data from NSDQ)

$19.58 USD

19.58
556,518

-0.35 (-1.76%)

Updated Mar 30, 2020 04:00 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.13%
17.51%
9.18%
4.92%
1.66%
10.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

C Value | C Growth | F Momentum | D VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Why Is National Vision (EYE) Down 37% Since Last Earnings Report?

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EYE

Zacks Equity Research

National Vision (EYE): Strong Industry, Solid Earnings Estimate Revisions

National Vision (EYE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

EYE

Zacks Equity Research

National Vision Grows on Positive Comps, Rising Costs a Woe

National Vision's (EYE) positive comparable store sales (comps) growth story continues for 72 consecutive quarters.

MDT RMD HRC EYE

Zacks Equity Research

National Vision (EYE) Rides on Robust Growth Across All Lines

National Vision (EYE) continues to register strong segmental performances.

SYK RMD STE EYE

Zacks Equity Research

Teleflex Hits New 52-Week High: What's Driving the Rally?

Teleflex (TFX) is optimistic about maintaining growth momentum on several recent developments.

TFX MDT HAE EYE

Zacks Equity Research

Thermo Fisher Rides on New Product Suite, Currency Woes Stay

Thermo Fisher Scientific (TMO) recently unveils a product suite comprising the TSQ Altis, Quantis MD mass spectrometers and Vanquish MD HPLC.

TMO MDT HAE EYE

Zacks Equity Research

Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod

Masimo (MASI) will cater to the whole prenatal patient population, with the recent FDA clearance within the SET pulse oximetry business.

MASI MDT HAE EYE

Zacks Equity Research

Hologic (HOLX) Divests Cynosure to Focus on Women's Health

Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.

HOLX MDT HAE EYE

Zacks Equity Research

Here's Why You Should Add NuVasive Stock to Your Portfolio

Investors continue to be optimistic about NuVasive (NUVA) on its stellar segmental performance in Q3.

MDT NUVA HAE EYE

Zacks Equity Research

Edwards (EW) Rides on Innovation Despite Regulatory Issues

Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.

EW HAE NUVA EYE

Zacks Equity Research

Product Launches Aid Intersect ENT (XENT) Despite Cost Woes

Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.

XENT RMD HAE EYE

Zacks Equity Research

Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts

Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.

BRKR HAE RMD EYE

Zacks Equity Research

Neogen (NEOG) Q2 Earnings & Revenues Miss, Margin Rises

Neogen Corporation (NEOG) disappoints investors with dismal second-quarter fiscal 2020 results. However, the Food Safety segment showcased a robust performance.

HAE NEOG RMD EYE

Zacks Equity Research

GNC Holdings Launches Energy Drink With Natural Extracts

GNC Holdings (GNC) launches natural ingredient-based energy drink MAD PONY ENERGY.

HAE RMD GNC EYE

Zacks Equity Research

NuVasive (NUVA) Soars to 52-Week High, Time to Cash Out?

NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NUVA HAE STE EYE

Zacks Equity Research

Neogen's (NEOG) Soleris for EBAC Receives AOAC's Clearance

Neogen's (NEOG) Soleris test gets clearance from the AOAC, paving the way for efficient prevention of food contamination.

HAE RMD NEOG EYE

Zacks Equity Research

EYE vs. AHCO: Which Stock Should Value Investors Buy Now?

EYE vs. AHCO: Which Stock Is the Better Value Option?

EYE AHCO

Zacks Equity Research

Zimmer Biomet Focuses on Priority Areas Despite Pricing Woes

Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.

HAE ZBH RMD EYE

Zacks Equity Research

Medtronic's (MDT) Brain Therapies Device Receives FDA Approval

Medtronic (MDT) strengthens its robotics platform with the receipt of regulatory approval and the subsequent upgradation of its enabling technology portfolio.

HAE MDT RMD EYE

Zacks Equity Research

Medtronic Acquires Klue to Strengthen Diabetes Management Arm

Medtronic (MDT) strengthens its diabetes business through the Klue acquisition and subsequent development of its PCL technology.

HAE RMD MDT EYE

Zacks Equity Research

Globus Medical Rides on New Product Menu, U.S. Spine Business

Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.

GMED HAE RMD EYE

Zacks Equity Research

Boston Scientific Hits New 52-Week High: What's Driving it?

Boston Scientific (BSX) is optimistic about sustaining the growth momentum on recent positive developments.

BSX RMD HAE EYE

Zacks Equity Research

Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod

Boston Scientific's (BSX) EXALT Model D single-use duodenoscope gets clearance from the FDA for use in ERCP procedures.

HAE RMD BSX EYE

Zacks Equity Research

Bruker Launches Luxendo TruLive3D Imager, Expands NANO Arm (Revised)

Bruker's (BRKR) latest Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environments.

BRKR HAE RMD EYE

Zacks Equity Research

CVS Health Rides on Aetna Prospects, Strong Selling Season

CVS Health's (CVS) 2020 PBM selling season is approaching closure and the 2021 selling season is ongoing.

RMD HAE CVS EYE